Drug Type Bispecific T-cell Engager (BiTE) |
Synonyms CMD007 |
Target |
Action stimulants, inhibitors |
Mechanism CD3 stimulants(T cell surface glycoprotein CD3 stimulants), MSLN inhibitors(Mesothelin inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedIND Application |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lung Cancer | IND Application | China | 23 Aug 2022 | |
Mesothelioma | IND Application | China | 23 Aug 2022 | |
Ovarian Cancer | IND Application | China | 23 Aug 2022 |